Sameera Peraramelli1,2, Qi Zhou1,2, Qin Zhou1,2, Bettina Wanko1,2,3, Lei Zhao1,2, Toshihiko Nishimura1,2, Thomas H Leung4, Seiya Mizuno5, Mamoru Ito6, Timothy Myles1, Thomas M Stulnig3,7, John Morser1,2, Lawrence L K Leung1,2. 1. Division of Hematology, Stanford University School of Medicine, Stanford, California, USA. 2. Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA. 3. Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna, Vienna, Austria. 4. Department of Dermatology, University of Pennsylvania School of Medicine, Pennsylvania, Pennsylvania, USA. 5. Laboratory Animal Resource Center, Trans-Border Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. 6. Central Institute for Experimental Animals (CIEA), Kawasaki, Japan. 7. Third Medical Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna, Austria.
Abstract
BACKGROUND: Osteopontin (OPN) is a multifunctional proinflammatory matricellular protein overexpressed in multiple human cancers and associated with tumor progression and metastases. Thrombin cleavage of OPN reveals a cryptic binding site for α4 β1 and α9 β1 integrins. METHODS: Thrombin cleavage-resistant OPNR153A knock-in (OPN-KI) mice were generated and compared to OPN deficient mice (OPN-KO) and wild type (WT) mice in their ability to support growth of melanoma cells. Flow cytometry was used to analyze tumor infiltrating leukocytes. RESULTS: OPN-KI mice engineered with a thrombin cleavage-resistant OPN had reduced B16 melanoma growth and fewer pulmonary metastases than WT mice. The tumor suppression phenotype of the OPN-KI mouse was identical to that observed in OPN-KO mice and was replicated in WT mice by pharmacologic inhibition of thrombin with dabigatran. Tumors isolated from OPN-KI mice had increased tumor-associated macrophages with an altered activation phenotype. Immunodeficient OPN-KI mice (NOG-OPN-KI) or macrophage-depleted OPN-KI mice did not exhibit the tumor suppression phenotype. As B16 cells do not express OPN, thrombin-cleaved fragments of host OPN suppress host antitumor immune response by functionally modulating the tumor-associated macrophages. YUMM3.1 cells, which express OPN, showed less tumor suppression in the OPN-KI and OPN-KO mice than B16 cells, but its growth was suppressed by dabigatran similar to B16 cells. CONCLUSIONS: Thrombin cleavage of OPN, derived from the host and the tumor, initiates OPN's tumor-promoting activity in vivo.
BACKGROUND: Osteopontin (OPN) is a multifunctional proinflammatory matricellular protein overexpressed in multiple human cancers and associated with tumor progression and metastases. Thrombin cleavage of OPN reveals a cryptic binding site for α4 β1 and α9 β1 integrins. METHODS: Thrombin cleavage-resistant OPNR153A knock-in (OPN-KI) mice were generated and compared to OPN deficient mice (OPN-KO) and wild type (WT) mice in their ability to support growth of melanoma cells. Flow cytometry was used to analyze tumor infiltrating leukocytes. RESULTS: OPN-KI mice engineered with a thrombin cleavage-resistant OPN had reduced B16 melanoma growth and fewer pulmonary metastases than WT mice. The tumor suppression phenotype of the OPN-KI mouse was identical to that observed in OPN-KO mice and was replicated in WT mice by pharmacologic inhibition of thrombin with dabigatran. Tumors isolated from OPN-KI mice had increased tumor-associated macrophages with an altered activation phenotype. Immunodeficient OPN-KI mice (NOG-OPN-KI) or macrophage-depleted OPN-KI mice did not exhibit the tumor suppression phenotype. As B16 cells do not express OPN, thrombin-cleaved fragments of host OPN suppress host antitumor immune response by functionally modulating the tumor-associated macrophages. YUMM3.1 cells, which express OPN, showed less tumor suppression in the OPN-KI and OPN-KO mice than B16 cells, but its growth was suppressed by dabigatran similar to B16 cells. CONCLUSIONS: Thrombin cleavage of OPN, derived from the host and the tumor, initiates OPN's tumor-promoting activity in vivo.
Authors: Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek Journal: Immunology Date: 2010-08-17 Impact factor: 7.397
Authors: Jochen Grassinger; David N Haylock; Melonie J Storan; Gemma O Haines; Brenda Williams; Genevieve A Whitty; Andrew R Vinson; Cheang Ly Be; Songhui Li; Esben S Sørensen; Patrick P L Tam; David T Denhardt; Dean Sheppard; Peter F Choong; Susan K Nilsson Journal: Blood Date: 2009-05-05 Impact factor: 22.113
Authors: Sandra S McAllister; Ann M Gifford; Ashley L Greiner; Stephen P Kelleher; Matthew P Saelzler; Tan A Ince; Ferenc Reinhardt; Lyndsay N Harris; Bonnie L Hylander; Elizabeth A Repasky; Robert A Weinberg Journal: Cell Date: 2008-06-13 Impact factor: 41.582
Authors: Jia Xue; Susanne V Schmidt; Jil Sander; Astrid Draffehn; Wolfgang Krebs; Inga Quester; Dominic De Nardo; Trupti D Gohel; Martina Emde; Lisa Schmidleithner; Hariharasudan Ganesan; Andrea Nino-Castro; Michael R Mallmann; Larisa Labzin; Heidi Theis; Michael Kraut; Marc Beyer; Eicke Latz; Tom C Freeman; Thomas Ulas; Joachim L Schultze Journal: Immunity Date: 2014-02-13 Impact factor: 31.745
Authors: Kate M Herum; Andreas Romaine; Ariel Wang; Arne Olav Melleby; Mari E Strand; Julian Pacheco; Bjørn Braathen; Pontus Dunér; Theis Tønnessen; Ida G Lunde; Ivar Sjaastad; Cord Brakebusch; Andrew D McCulloch; Maria F Gomez; Cathrine R Carlson; Geir Christensen Journal: J Am Heart Assoc Date: 2020-01-31 Impact factor: 5.501